Nobuto Yamamoto

Summary

Country: USA

Publications

  1. ncbi A new procedure for experimental autoimmune uveitis with small uveitogenic peptides
    Theodore W Sery
    Research Division, and Pathology Service, Wills Eye Hospital and Thomas Jefferson University, 840 Walniut Street, Philadelphia, PA 19107, USA
    Ocul Immunol Inflamm 14:277-83. 2006
  2. ncbi Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus
    Nobuto Yamamoto
    Division of Molecular Biology and Virology, Socrates Institute for Therapeutic Immunology, 1040 66th Avenue, Philadelphia, PA 19126 3305, USA
    Microbes Infect 7:674-81. 2005
  3. ncbi Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126 3305, USA
    Int J Cancer 122:461-7. 2008
  4. ncbi Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Immunology, Socrates Institute for Therapeutic Immunology, 1040, 66th Ave, Philadelphia, PA 19126 3305, USA
    Cancer Immunol Immunother 57:1007-16. 2008
  5. ncbi Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)
    Nobuto Yamamoto
    Division of Molecular Immunology and Immunotherapy, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania 19126 3305, USA
    J Med Virol 81:16-26. 2009
  6. ncbi Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126 3305, USA
    Transl Oncol 1:65-72. 2008
  7. ncbi Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus Type 1
    Nobuto Yamamoto
    Division of Molecular Virology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania 19126 3305, USA
    AIDS Res Hum Retroviruses 22:262-71. 2006
  8. ncbi Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis
    Shigeru Kanda
    Department of Molecular Microbiology and Immunology, Division of Endothelial Cell Biology, Nagasaki University Graduate School of Medicine, Nagasaki, Japan
    J Natl Cancer Inst 94:1311-9. 2002

Detail Information

Publications8

  1. ncbi A new procedure for experimental autoimmune uveitis with small uveitogenic peptides
    Theodore W Sery
    Research Division, and Pathology Service, Wills Eye Hospital and Thomas Jefferson University, 840 Walniut Street, Philadelphia, PA 19107, USA
    Ocul Immunol Inflamm 14:277-83. 2006
    ..Demonstration of experimental autoimmune uveitis (EAU) with extremely small, fragmented peptides (12-30 amino acid residues) of interphotoreceptor retinoid-binding protein (IRPB)...
  2. ncbi Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus
    Nobuto Yamamoto
    Division of Molecular Biology and Virology, Socrates Institute for Therapeutic Immunology, 1040 66th Avenue, Philadelphia, PA 19126 3305, USA
    Microbes Infect 7:674-81. 2005
    ..Thus, Nagalase plays dual roles in regulating both infectivity and immunosuppression...
  3. ncbi Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126 3305, USA
    Int J Cancer 122:461-7. 2008
    ..38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years...
  4. ncbi Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Immunology, Socrates Institute for Therapeutic Immunology, 1040, 66th Ave, Philadelphia, PA 19126 3305, USA
    Cancer Immunol Immunother 57:1007-16. 2008
    ..During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients...
  5. ncbi Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)
    Nobuto Yamamoto
    Division of Molecular Immunology and Immunotherapy, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania 19126 3305, USA
    J Med Virol 81:16-26. 2009
    ..No recurrence occurred and their healthy CD + cell counts were maintained for 7 years...
  6. ncbi Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF
    Nobuto Yamamoto
    Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126 3305, USA
    Transl Oncol 1:65-72. 2008
    ..No recurrence occurred for 7 years...
  7. ncbi Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the envelope glycoprotein gp160 of human immunodeficiency virus Type 1
    Nobuto Yamamoto
    Division of Molecular Virology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania 19126 3305, USA
    AIDS Res Hum Retroviruses 22:262-71. 2006
    ..Therefore, Nagalase appears to play dual roles in viral infectivity and immunosuppression...
  8. ncbi Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis
    Shigeru Kanda
    Department of Molecular Microbiology and Immunology, Division of Endothelial Cell Biology, Nagasaki University Graduate School of Medicine, Nagasaki, Japan
    J Natl Cancer Inst 94:1311-9. 2002
    ..We investigated whether GcMAF also acts as an antiangiogenic factor on endothelial cells...